Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 10/2008

01.10.2008 | Article

Serological microarray for a paradoxical diagnostic of Whipple’s disease

verfasst von: C. J. Bonhomme, P. Renesto, S. Nandi, A. M. Lynn, D. Raoult

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Whipple’s disease is a systemic chronic infection caused by Tropheryma whipplei. Asymptomatic people may carry T. whipplei in their digestive tract and this can be determined by PCR, making serological diagnosis useful to distinguish between carriers and patients. Putative antigenic proteins were selected by computational analysis of the T. whipplei genome, immunoproteomics studies and from literature. After expression, putative T. whipplei antigens were screened by microimmunofluorescence with sera of immunized rabbit. Selected targets were screened by microarray using sera from patients and carriers. Paradoxically, with 19 tested recombinant proteins and a glycosylated native protein of T. whipplei, a higher immune response was observed with asymptomatic carriers. In contrast, quantification of human IgA exhibited a higher reaction in patients than in carriers against 10 antigens. These results were used to design a diagnostic test with a cut-off value for each antigen. A blind test assay was performed and was able to diagnose 6/8 patients and 11/12 carriers. Among people with positive T. whipplei PCR of the stool, patients differ from carriers by having positive IgA detection and a negative IgG detection. If confirmed, this serological test will distinguish between carriers and patients in people with positive PCR of the stool.
Literatur
1.
Zurück zum Zitat La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D (2001) Description of Tropheryma whipplei gen.nov., sp.nov., the Whipple’s disease bacillus. Int J Syst Evol Microbiol 51:1471–1479PubMed La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D (2001) Description of Tropheryma whipplei gen.nov., sp.nov., the Whipple’s disease bacillus. Int J Syst Evol Microbiol 51:1471–1479PubMed
2.
Zurück zum Zitat Wilson KH, Blitchington R, Frothingham R, Wilson JA (1991) Phylogeny of the WhippIe’s-disease-associated bacterium. Lancet 338:474–475PubMedCrossRef Wilson KH, Blitchington R, Frothingham R, Wilson JA (1991) Phylogeny of the WhippIe’s-disease-associated bacterium. Lancet 338:474–475PubMedCrossRef
3.
Zurück zum Zitat Relman DA, Schmidt TM, MacDermott RP, Falkow S (1992) Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med 327:293–301PubMed Relman DA, Schmidt TM, MacDermott RP, Falkow S (1992) Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med 327:293–301PubMed
4.
Zurück zum Zitat Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital Durand D, Marrie TJ (2000) Cultivation of the bacillus of Whipple’s disease. New Engl J Med 342:620–625PubMedCrossRef Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital Durand D, Marrie TJ (2000) Cultivation of the bacillus of Whipple’s disease. New Engl J Med 342:620–625PubMedCrossRef
5.
Zurück zum Zitat Renesto P, Crapoulet N, Ogata H, La Scola B, Vestris G, Claverie JM, Raoult D (2003) Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 362:447–449PubMedCrossRef Renesto P, Crapoulet N, Ogata H, La Scola B, Vestris G, Claverie JM, Raoult D (2003) Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 362:447–449PubMedCrossRef
6.
Zurück zum Zitat Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE, Von Herbay A, Goble A, Rutter S, Squares R, Squares S, Barrell BG, Parkhill J, Relman DA (2003) Sequencing and analysis of the genome of the Whipple’s disease bacterium Tropheryma whipplei. Lancet 361:637–644PubMedCrossRef Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE, Von Herbay A, Goble A, Rutter S, Squares R, Squares S, Barrell BG, Parkhill J, Relman DA (2003) Sequencing and analysis of the genome of the Whipple’s disease bacterium Tropheryma whipplei. Lancet 361:637–644PubMedCrossRef
7.
Zurück zum Zitat Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM (2003) Tropheryma whipplei twist: a human pathogenic actinobacteria with a reduced genome. Genome Res 13:1800–1809PubMed Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM (2003) Tropheryma whipplei twist: a human pathogenic actinobacteria with a reduced genome. Genome Res 13:1800–1809PubMed
8.
Zurück zum Zitat Kowalczewska M, Fenollar F, Lafitte D, Raoult D (2006) Identification of candidate antigen in Whipple’s disease using a serological proteomic approach. Proteomics 6:3294–3305PubMedCrossRef Kowalczewska M, Fenollar F, Lafitte D, Raoult D (2006) Identification of candidate antigen in Whipple’s disease using a serological proteomic approach. Proteomics 6:3294–3305PubMedCrossRef
9.
11.
12.
Zurück zum Zitat Maiwald M, Relman D (2001) Whipple’s disease and Tropheryma whippelii: secrets slowly revealed. Clin Infect Dis 32:457–463PubMedCrossRef Maiwald M, Relman D (2001) Whipple’s disease and Tropheryma whippelii: secrets slowly revealed. Clin Infect Dis 32:457–463PubMedCrossRef
13.
Zurück zum Zitat Mahnel R, Marth T (2004) Progress, problems, and perspectives in diagnosis and treatment of Whipple’s disease. Clin Exp Med 4:39–43PubMedCrossRef Mahnel R, Marth T (2004) Progress, problems, and perspectives in diagnosis and treatment of Whipple’s disease. Clin Exp Med 4:39–43PubMedCrossRef
14.
Zurück zum Zitat Black-Schaffer B (1949) The tinctoral demonstration of a glycoprotein in Whipple’s disease. Proc Soc Exp Biol 72:225–227 Black-Schaffer B (1949) The tinctoral demonstration of a glycoprotein in Whipple’s disease. Proc Soc Exp Biol 72:225–227
16.
Zurück zum Zitat Schoniger-Hekele M, Petermann D, Weber B, Muller C (2007) Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 73:2033–2035PubMedCrossRef Schoniger-Hekele M, Petermann D, Weber B, Muller C (2007) Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 73:2033–2035PubMedCrossRef
17.
Zurück zum Zitat Fenollar F, Trani M, Davoust B, Salle B, Birg ML, Rolain JM, Raoult D (2008) Carriage of Tropheryma whipplei in stools of sewer workers and human controls, but not in monkeys and apes. J Infect Dis In press Fenollar F, Trani M, Davoust B, Salle B, Birg ML, Rolain JM, Raoult D (2008) Carriage of Tropheryma whipplei in stools of sewer workers and human controls, but not in monkeys and apes. J Infect Dis In press
18.
Zurück zum Zitat Li W, Fenollar F, Rolain JM, Fournier PE, Feurle GE, Muller C, Moos A, Marth T, Altwegg M, Calligaris-Maibach R, Schneider T, Biagi F, La Scola B, Raoult D (2008) Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 154:527 Li W, Fenollar F, Rolain JM, Fournier PE, Feurle GE, Muller C, Moos A, Marth T, Altwegg M, Calligaris-Maibach R, Schneider T, Biagi F, La Scola B, Raoult D (2008) Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 154:527
19.
Zurück zum Zitat Desnues B, Raoult D, Mege JL (2005) IL-16 is critical for Tropheryma whipplei replication in Whipple’s disease. J Immunol 175:4575–4582PubMed Desnues B, Raoult D, Mege JL (2005) IL-16 is critical for Tropheryma whipplei replication in Whipple’s disease. J Immunol 175:4575–4582PubMed
20.
Zurück zum Zitat Desnues B, Ihrig M, Raoult D, Mege JL (2006) Whipple’s disease: a macrophage disease. Clin Vaccine Immunol 13:170–178PubMedCrossRef Desnues B, Ihrig M, Raoult D, Mege JL (2006) Whipple’s disease: a macrophage disease. Clin Vaccine Immunol 13:170–178PubMedCrossRef
21.
Zurück zum Zitat Benoit M, Fenollar F, Raoult D, Mege JL (2007) Increased levels of circulating IL-16 and apoptosis markers are related to the activity of Whipple’s Disease. PLoS ONE 2:e494PubMedCrossRef Benoit M, Fenollar F, Raoult D, Mege JL (2007) Increased levels of circulating IL-16 and apoptosis markers are related to the activity of Whipple’s Disease. PLoS ONE 2:e494PubMedCrossRef
22.
Zurück zum Zitat Kowalczewska M, Fenollar F, Villard C, Azza S, Roux M, Raoult D (2008) An immunoproteomic approach for identification of clinical biomarkers of Whipple’s disease. Proteomics Clin Appl In press Kowalczewska M, Fenollar F, Villard C, Azza S, Roux M, Raoult D (2008) An immunoproteomic approach for identification of clinical biomarkers of Whipple’s disease. Proteomics Clin Appl In press
23.
Zurück zum Zitat Bacarese-Hamilton T, Bistoni F, Crisanti A (2002) Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques Suppl:S24-S29 Bacarese-Hamilton T, Bistoni F, Crisanti A (2002) Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques Suppl:S24-S29
24.
Zurück zum Zitat Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, Rossi R, Bistoni F, Crisanti A (2002) Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem 48:121–130PubMed Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, Rossi R, Bistoni F, Crisanti A (2002) Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem 48:121–130PubMed
25.
Zurück zum Zitat Steller S, Angenendt P, Cahill DJ, Heuberger S, Lehrach H, Kreutzberger J (2005) Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics 5:2048–2055PubMedCrossRef Steller S, Angenendt P, Cahill DJ, Heuberger S, Lehrach H, Kreutzberger J (2005) Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics 5:2048–2055PubMedCrossRef
26.
Zurück zum Zitat Bonhomme CJ, Nappez C, Raoult D (2007) Microarray for serotyping of Bartonella species. BMC Microbiol 7:59PubMedCrossRef Bonhomme CJ, Nappez C, Raoult D (2007) Microarray for serotyping of Bartonella species. BMC Microbiol 7:59PubMedCrossRef
27.
Zurück zum Zitat Gouriet F, Drancourt M, Raoult D (2006) Multiplexed serology in atypical bacterial pneumonia. Ann N Y Acad Sci 1078:530–540PubMedCrossRef Gouriet F, Drancourt M, Raoult D (2006) Multiplexed serology in atypical bacterial pneumonia. Ann N Y Acad Sci 1078:530–540PubMedCrossRef
28.
Zurück zum Zitat Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timmis J (eds) ICARIS, LNCS. Springer, pp 197–204 Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timmis J (eds) ICARIS, LNCS. Springer, pp 197–204
29.
Zurück zum Zitat Rolain JM, Lecam C, Raoult D (2003) Simplified serological diagnosis of endocarditis due to Coxiella burnetii and Bartonella. Clin Diagn Lab Immunol 10:1147–1148PubMedCrossRef Rolain JM, Lecam C, Raoult D (2003) Simplified serological diagnosis of endocarditis due to Coxiella burnetii and Bartonella. Clin Diagn Lab Immunol 10:1147–1148PubMedCrossRef
30.
Zurück zum Zitat Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef
31.
Zurück zum Zitat Sagara K, Matsuyama S, Mizushima S (1994) SecF stabilizes SecD and SecY, components of the protein translocation machinery of the Escherichia coli cytoplasmic membrane. J Bacteriol 176:4111–4116PubMed Sagara K, Matsuyama S, Mizushima S (1994) SecF stabilizes SecD and SecY, components of the protein translocation machinery of the Escherichia coli cytoplasmic membrane. J Bacteriol 176:4111–4116PubMed
32.
Zurück zum Zitat Gouriet F, Levy PY, Samson L, Drancourt M, Raoult D (2008) Comparison of multiplexed slides InoDiag automate immunofluorescence to reference serology in the diagnosis of atypical bacterial pneumonia. Clin Microbiol Infect submitted Gouriet F, Levy PY, Samson L, Drancourt M, Raoult D (2008) Comparison of multiplexed slides InoDiag automate immunofluorescence to reference serology in the diagnosis of atypical bacterial pneumonia. Clin Microbiol Infect submitted
33.
34.
Zurück zum Zitat Walhout AJ, Temple GF, Brasch MA, Hartley JL, Lorson MA, van den Heuvel S, Vidal M (2000) GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol 328:575–592PubMedCrossRef Walhout AJ, Temple GF, Brasch MA, Hartley JL, Lorson MA, van den Heuvel S, Vidal M (2000) GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol 328:575–592PubMedCrossRef
35.
Zurück zum Zitat Lepidi H, Fenollar F, Gerolami R, Mege JL, Bonzi MF, Chappuis M, Sahel J, Raoult D (2003) Whipple’s disease: Immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 34:589–596PubMedCrossRef Lepidi H, Fenollar F, Gerolami R, Mege JL, Bonzi MF, Chappuis M, Sahel J, Raoult D (2003) Whipple’s disease: Immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 34:589–596PubMedCrossRef
36.
Zurück zum Zitat Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef
37.
Zurück zum Zitat Kalt A, Schneider T, Ring S, Hoffmann J, Zeitz M, Stallmach A, Persing DH, Marth T (2006) Decreased levels of interleukin-12p40 in the serum of patients with Whipple’s disease. Int J Colorectal Dis 21:114–120PubMedCrossRef Kalt A, Schneider T, Ring S, Hoffmann J, Zeitz M, Stallmach A, Persing DH, Marth T (2006) Decreased levels of interleukin-12p40 in the serum of patients with Whipple’s disease. Int J Colorectal Dis 21:114–120PubMedCrossRef
38.
Zurück zum Zitat Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T (2005) Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 100:1167–1173PubMedCrossRef Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T (2005) Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 100:1167–1173PubMedCrossRef
Metadaten
Titel
Serological microarray for a paradoxical diagnostic of Whipple’s disease
verfasst von
C. J. Bonhomme
P. Renesto
S. Nandi
A. M. Lynn
D. Raoult
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2008
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0528-0

Weitere Artikel der Ausgabe 10/2008

European Journal of Clinical Microbiology & Infectious Diseases 10/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.